People Archive

Dr. Ira Kirschenbaum Contributions to Orthopedics

Over the past few years, Dr. Ira Kirschenbaum has been a noted specialist in knee, hip, and shoulder replacements. He’s also been serving as the Chairman of Orthopedics at Bronx care Health System. However, it’s not his surgical skills that have landed him positive attention, but his overall contributions to Orthopedics.

Dr. Ira Kirschenbaum began his undergraduate studies at Brown University before moving on to study medicine at Yeshiva University’s Albert Einstein College of Medicine. After completing his residency, he had a fellowship in Orthopedic Surgery at the Rothman Institute. It was then that he began his entrepreneurial streak when he went to Harvard Business School after he completed his medical training and earned a certificate in health care delivery management.

He followed this by founding or co-founding some medical organizations with the most notable being Medscape. GQ and WebMD quickly bought this. Following this, he also served as a Community Health Editor for WebMD. Known in the field as an innovator, Dr. Ira Kirschenbaum has specialized in process engineering and information technology. Because of that background, he was able to design multiple joint replacement systems that are standard practice today.

On top of the thousands of successful joint replacement surgeries he has performed, Dr. Ira Kirschenbaum has delivered extensive lectures and published books and articles about orthopedic surgery. It isn’t just public praise that he’s earned, but also a vast number of awards.

Many of these have focused on his innovation, ethics and quality care. These awards and accolades can be traced back to Dr. Ira Kirschenbaum’s investment in his patients and staff. When asked about what habits are essential to productivity in the health care industry, he replied by saying connecting with each of his colleagues was the best practice possible. This link provides more information about how networking has helped him change the field of Orthopedics.

Not only did he make it a habit of reaching out on a regular basis, but he also held regular meetings with key staff. These meetings were extremely focused and aimed at providing the best care possible to patients. Advancements in technology are always driving health care, and Dr. Ira Kirschenbaum has always been a pioneer in this regard. In recent years, he’s also helped to increase the awareness for the benefits of 3D technology and robotic technologies in surgery.

Dr. Panos Gikas Considered a Leader in Medical Treatment and Research

Dr. Panos Gikas is considered a leader when it comes to providing treatment and conducting research in the areas of hip, knee and bone cancer surgery. He currently serves as a consulting orthopedic and sarcoma surgeon at the Royal National Orthopedic Hospital in Stanmore, England, a suburb of London.

Having received both a Ph.D. degree in general surgery from the University of Athens, in Greece, and a medical degree in orthopedic surgery from University College London, Dr. Panos Gikas would go on to complete a fellowship in trauma and orthopedics at the Royal College of Surgeons, also in England. Additionally, he completed a fellowship at the Royal Prince Alfred Hospital in Australia, where he received training in the treatment of bone tumors, and another in Switzerland, where he honed his skills in the anterior muscle sparing hip replacement technique.

In addition to his abilities in treating bone and soft tissue cancer, his background allows him to concentrate on hip and knee replacement surgery. Specific to the practice of joint replacements, Dr. Panos Gikas employs custom-made implants, robotic joint methods, arthroscopic surgical techniques and stem cell technology. Dr. Panos Gikas also has expertise in removing benign and malignant tumors from bones and from areas of soft tissue within the body, with this work carried out in association with the London Sarcoma Service.

The use by Dr. Panos Gikas of the anterior approach to hip replacement makes it possible to perform surgery from the front, thus avoiding the invasive procedure associated with conventional surgery. The anterior approach is considered minimally invasive, which reduces both the size of the surgical scar and the recovery time. It also reduces the chance of a bone dislocation. The use of minimally invasive procedures makes Dr. Panos Gikas an invaluable player in the British surgical scene. This is especially true when considering the high demand for joint replacement surgery in Great Britain, with more than 4 million of the nation’s citizens currently waiting for the procedure.

Throughout his medical career, Dr. Panos Gikas has shown interest in the research and educational aspects of medicine, having taken his knowledge far beyond the surgery room. He has written seven book chapters and more than 30 published papers on the subject. His current research includes an examination of endoprosthetic implant methods that could be used in the future. Dr. Panos Gikas also devotes considerable time to teaching future orthopedic surgeons. In addition to mentoring students at his hospital, he is a participant in a London North Thames orthopedic instruction program. He also conducts lectures on musculoskeletal issues at his alma mater, University College London.

Among his professional memberships, Dr. Panos Gikas belongs to the Royal Society of Medicine and is on the specialty register of the General Medical Council. Outside of his medical practices, Dr. Panos Gikas may be be seen on the water, either in a boat or sliding behind one on water skis. Click this link to see Dr. Panos Gikas profile.

Marc Beer’s Renovia Raises $42 Million For The Advancement Of Women Health

Marc Beer recently co-founded a health startup, Renovia Inc. dedicated to the advancement of women health research. The firm particularly specializes in the study and development of drugs and other treatment options for urinary incontinence.

 

According to Renovia, this refers to a pelvic floor disorder estimated to affect over 250 million women across the world. Marc’s startup has, therefore, dedicated vast amounts of time and resources in understanding the condition and developing its first drug, Leva, which received FDA’s approval in April.

 

Raising $42 Million

 

Renovia sources its funds from healthcare investment firms to advance its objectives. The Marc Beer-led company would start by organizing a series A funding to get the ball rolling. The funds raised during the Series A round would help the firm initiate different research projects that culminated in the development and approval of their first pelvic floor disorder drug, Leva.

 

The women health startup has, however, been engaged in several other research and drug development projects. For instance, it is contemplating the development of an advanced form of the Leva drug. More importantly, it has four diagnostic and therapeutic products that it hopes to push through the final development, testing and approval process.

 

It, therefore, organized a successful Series B round of funding that raised a record $42 Million. Missouri-based Ascension ventures and the Longwood Fund were some of the earliest venture capitalists to join the fund drive that Raised $42 million. A significant portion of this, $32 Million, was in the form of direct investments while venture debt accounted for $10 million.

 

Marc Beer’s optimism

 

Acknowledging the success of the Series B funding, Marc Beer praised the healthcare investment funds for their support. He would interpret the success of the fund drive as a show of approval and support of Renovia’s mission and vision. Marc added that his company has access to a host of highly innovative and proprietary healthcare technologies. These help it gain a deeper understanding of the pelvic floor disorders and in effect develop more effective treatment options. Learn more: https://ideamensch.com/marc-beer/

 

More about Marc Beer

 

Marc has close to three decades of active experience in the health sector. He spent a significant portion of this time in the biotechnology, pharmaceuticals, diagnostics, and devices sectors where he helped to promote research and aid with the commercialization of treatment options. Taking advantage of this industry experience, Marc partnered with Yolanda Lorie and Ramon Iglesias to co-found Renovia Inc. in 2016 where he serves as the Managing Director.

 

He shot into the drug research and commercialization limelight during his time at ViaCell, a biotechnology startup specializing in the collection and preservation of umbilical cord and blood stem cells. He led the company for seven years and saw it morph from a simple startup to a fully-fledged commercial organization employing over 300 employees.

 

Scott Rocklage and 5AM Ventures Help Secure Funding for MD1 Research

Expansion Therapeutic has recently begun working on a campaign to raise series A funding for the purpose of increasing the efforts that it is making toward research into fighting a wide variety of genetic conditions in their portfolio of concern. Chief among these conditions is myotonic dystrophy type I which is a precursor disorder that is the leading cause of Adult Muscular Dystrophy. The currently accepted research indicated that the symptoms of DM1 begin to manifest once RNA levels reach toxic.

 

What has been found is that the production of some RNAs eventfully becomes toxic and trigger the effects of DM1. Unlike regular RNAs, molecules that are released from DNA strands and eventually convert into protein molecules which usually are harmless, these particular RNAs can have severe adverse reactions in the cells that contain them. The cells that are most susceptible this toxic RNA activity are the ones which are located in the heart, endocrine system, gastrointestinal tract, respiratory system, and central nervous system. As the cells at compromised the systems become defective and start to fail.

 

DM1 can affect entire families and can become worse with each subsequent generation. Expansion Therapeutics is committed to finding a solution to the problem of DM1. There is currently no known cure or treatment for DM1, but Expansion Therapeutics feels that they are on the right track. With the new resource pool of funding that was acquired by the campaign, this effort can now continue until a cure is found.

 

The funding campaign was led by Novartis Venture Fund, Sanofi Ventures, Kleiner Perkins, and 5AM ventures with Alexandria Venture Investments and RA Capital Management also being attached. A press release was issued by the managing partner of 5Am Ventures, Scott Rocklage on the funding campaign. Rocklage has been a leader in helping to fund advancements in medical research of all types with the goal being to help advance the understanding of illness and increase the benefits of medical science for mankind. Learn more: https://www.linkedin.com/in/scott-rocklage-66aa7a12a

 

Scott Rocklage has devoted his life, both in business and in the realm of science to the advancement of the understating of how science can be applied to the real world problems of everyday people. He started his company 5AM ventures to provide investment opportunities to those who share his dreams of a better world and to provide a secure source of funding to those research organizations and companies that are looking for cures to the worlds most incredulous diseases and conditions. He is a man who has spent the better part of his adulthood working to better the lives of others and continues to find new ways to make the world a better place every day in any way possible.